P

Pfizer

Makes cancer drugs, vaccines and other medicines

Senior Vaccine Clinician

Full-Time
No salary listed
Senior
Beijing, China+1 moreMore locations: Shanghai, China
In Person
Biology & BiotechClinical Research Operations

About the job

Responsibilities
  • Deliver one or more interventional clinical trials for R&D in a timely, high-quality manner, including designing cost-efficient trials, overseeing study conduct and medical/scientific matters with the clinical trial manager, interpreting and communicating trial data, supporting regulatory submissions and product defense, ensuring standards compliance, mitigating risk, and managing clinical issues.
  • Act as a site liaison and point of contact to expedite study start-up and conduct and support clinical training, compliance, and study quality, as applicable.
  • Co-chair clinical study teams and collaborate with study team members.
  • Be accountable to the business unit for the design, conduct, interpretation, and reporting of one or more clinical studies or study elements.
  • Provide clinical and scientific expertise for clinical trial strategy and protocol development, including knowledge of competitor products.
  • Apply Enhanced Clinical Trial Design and Enhanced Quantitative Drug Development to develop efficient clinical protocols.
  • Design and write clinical trial outlines, protocols, and amendments with internal contributors and experts and external experts, ensuring alignment with study objectives.
  • Author efficient protocols that minimize amendments; identify and assess risks to good clinical practice, subject rights and safety, and data integrity during protocol development and study conduct; create, implement, and assess mitigation plans.
  • Provide clinical input to study teams on monitoring guidelines, iQ RAMP, statistical analysis plans, informed consent documents, clinical review forms, data edit checks, data-quality planning, and regional medical-monitor medical-oversight plans, and oversee study-team work as needed.
  • Contribute to contract research organization and vendor selection to ensure conduct aligns with protocol requirements, clinical-plan expectations, and study timelines, including applying medical and technical data-integrity requirements such as laboratory specifications.
  • Approve selection of countries, clinical sites, and investigators with suitable qualifications, patient populations, and recruitment strategies to meet study goals on time and with high quality and cost-effectiveness.
  • Ensure studies are registered on ClinicalTrials.gov, details remain current, and basic results are disclosed as required.
  • Create and, where appropriate, deliver clinical and protocol training materials for study and site management and for site initiation visits and investigator meetings.
  • Help establish and oversee data monitoring committees and endpoint adjudication committees, including charters, contracts, data provision, and outcome documentation.
  • Share accountability with the study team for enrollment and adherence to agreed timelines for study deliverables.
  • Maintain direct contact with investigative sites through visits and other communications to support investigator engagement, answer protocol or investigational-product questions, and facilitate enrollment, coordinating with regional clinical site leads where assigned; take on expanded site-liaison responsibilities for some studies.
  • Review individual-subject and cumulative safety data regularly and document reviews in accordance with the safety review plan, with the safety risk lead and a designated medically qualified medical monitor.
  • Identify emerging safety trends, raise them with clinical program leads, and follow up with investigators on specific safety findings such as serious adverse events.
  • Review and manage protocol deviations.
  • Work with study teams to ensure data quality, including suitable patient populations and adequate clinical assessments.
  • Conduct clinical review and interpretation of trial efficacy and safety data; deliver top-line reports with study statisticians and clinical study reports with medical writers; ensure analysis and reporting are high-quality and timely.
  • Ensure the clinical and scientific validity of study reports, especially efficacy and safety conclusions, and disclose appropriate safety and efficacy data and conclusions.
  • Ensure trial safety narratives align with program narrative strategy and write or oversee safety narratives.
  • Support regulatory compliance for clinical trials and reporting and contribute to primary publication of trial results.
  • Serve as primary contact for external investigators and internal study teams on clinical or medical protocol questions, as applicable.
  • Keep clinical program and category development leads informed of critical benefit-risk or study-delivery issues relating to budget, timelines, or quality.
  • Present clinical trial designs and data to internal and external advisory committees.
  • When assigned site-liaison duties, support trial conduct through virtual meetings, teleconferences, and essential in-person contact with site staff; maintain Pfizer's presence at sites and build positive relationships.
  • Understand clinical-site work environments and key relationships, and use analytical and influencing skills to improve stakeholder communication and collaboration.
  • Ensure site staff understand protocol requirements; partner with site staff and study teams to overcome feasibility barriers and operational obstacles and support successful subject recruitment, enrollment, retention, protocol compliance, and trial quality.
  • Discuss site performance expectations and monitor performance through metrics.
  • Identify site quality issues and discuss them with clinical and operations study teams so corrective actions can be implemented; escalate medical protocol issues to regional or medically qualified clinical leads and operational issues to appropriate operations team members.
  • Identify where site staff need support, coaching, or training and provide it as appropriate.
  • Identify successful sites' methods, techniques, relationships, and logistical approaches and transfer best practices to other sites.
  • Motivate and engage colleagues in understanding disease and commitment to an indication and mechanism.
  • Coach and mentor less experienced clinicians and, where applicable, directly manage clinicians.
  • Maintain and enhance knowledge in relevant disease and technical areas and practice guidelines applicable to trial regions.
  • Share best practices with other Pfizer sites, business units, and functions as appropriate.
  • Organize expert-panel, consultant, or advisory-board meetings to provide input on protocols, clinical plans, or data analysis, as applicable.
  • Provide clinical assistance for scientific and commercialization support for approved medicines, co-promotions, product defense, and clinical consultation on epidemiology and outcomes-research studies.
  • Assist with developing publications, abstracts, and presentations.
  • Lead or assist in preparing clinical content for regulatory submissions and documents, including new drug applications, marketing authorization applications, investigational new drug applications, supplemental new drug applications, investigator brochures, and annual reports.
  • Assist in regulator discussions and resolving queries from drug regulatory agencies and ethics committees; lead or contribute to writing and reviewing responses to regulatory queries.
  • Support technical review of licensing opportunities, including due diligence, as applicable.
  • Ensure compliance with global and local training requirements and applicable controlled clinical and medical documents.
  • Contribute to or lead continuous-improvement activities and education and training of clinical staff in areas of competence or experience.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.